CMS Picks Next Drugs for Medicare Price Negotiations

January 28, 2026

CMS this week announced the next 15 prescription drugs selected to participate in its Medicare drug price negotiation program for 2026.

For the first time, the next round of negotiations will include drugs covered under both Medicare Part D and Part B. The government also has selected the diabetes drug Tradjenta from a previous round for renegotiations this year.

Here’s what you need to know:

• Round three selections: The drugs included are: Anoro Ellipta; Biktarvy; Botox/Botox Cosmetic; Cimzia; Cosentyx; Entyvio; Erleada; Kisqali; Lenvima; Orencia; Rexulti; Trulicity; Verzenio; Xeljanz/Xeljanz XR; and Xolair.
• Timing:  Negotiations will begin this year, with prices effective January 1, 2028.
• About the selections:  CMS released the top 50 negotiation-eligible drugs based on combined expenditures under Medicare Parts B and D.
  • The drugs selected for the third cycle were the top 15 highest-spending drugs on this list. 
  • These drugs account for $27 billion in total prescription drug spending under Medicare Part B and Part D, or about 6 percent, officials said.
• Background:  The Medicare Drug Price Negotiation Program was established as part of the 2022 Inflation Reduction Act. Previous negotiations have led to new prices for drugs for diabetes, blood clots, weight loss, cancer, and arthritis, among other conditions.
• Quotable: “By applying clear eligibility criteria and practical negotiation policies, we are ensuring the program responds to market changes while delivering fairness and value for the American people,” said CMS Deputy Administrator and Director of Medicare Chris Klomp.

The manufacturers of the selected products have until February 28 to decide if they will participate in negotiations. Additional information from CMS, including a fact sheet, is available online.